Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma

Tamura, Ryo; Yoshihara, Kosuke; Matsuo, Koji; Yachida, Nozomi; Miyoshi, Anderson; Takahashi, Kotaro; Sugino, Kentaro; Yamaguchi, Manako; Mori, Yutaro; Suda, Kazuaki; Ishiguro, Takehiko; Okuda, Shujiro; Motoyama, Teiichi; Nakaoka, Hirofumi; Kikuchi, Akira; Ueda, Yutaka; Inoue, Ituro; Enomoto, Takayuki

doi:10.1016/j.ygyno.2021.08.009

Cited by 8 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total RNA extraction and library preparation were performed as previously reported. 51 Briefly, total RNA was extracted from frozen samples of OCCC (30 cases) using TRIzol (#15596026, Invitrogen), and then subjected to cDNA library preparation by using a TruSeq Stranded mRNA Library Prep Kit (RS-20020595, Illumina), according to the manufacturer’s instructions. Subsequently, cDNA libraries were sequenced on the Illumina HiSeq 2500 platform with the 2 × 100-bp paired-end read module.…”

Section: Methodsmentioning

confidence: 99%

Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1α and tumor progression of clear cell ovarian cancer

Mori,

Okimoto,

Sakai

et al. 2024

Cell Reports Medicine

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1α and tumor progression of clear cell ovarian cancer

Mori,

Okimoto,

Sakai

et al. 2024

Cell Reports Medicine

Self Cite

View full text Add to dashboard Cite

“…VTE is more common in advanced OCCC cases and more frequent than other histologic types of OC [ 240 ]. In addition, VTE is also considered an independent risk factor for OCCC as it increases the risk of various adverse events, including cardiovascular accidents and postoperative complications during the OCCC treatment [ 241 ].…”

Section: Prognostic Factorsmentioning

confidence: 99%

From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer

Liu,

Jing,

Kong

2024

J Ovarian Res

View full text Add to dashboard Cite

Ovarian clear-cell cancer is a rare subtype of epithelial ovarian cancer with unique clinical and biological features. Despite optimal cytoreductive surgery and platinum-based chemotherapy being the standard of care, most patients experience drug resistance and a poor prognosis. Therefore, novel therapeutic approaches have been developed, including immune checkpoint blockade, angiogenesis-targeted therapy, ARID1A synthetic lethal interactions, targeting hepatocyte nuclear factor 1β, and ferroptosis. Refining predictive biomarkers can lead to more personalized medicine, identifying patients who would benefit from chemotherapy, targeted therapy, or immunotherapy. Collaboration between academic research groups is crucial for developing prognostic outcomes and conducting clinical trials to advance treatment for ovarian clear-cell cancer. Immediate progress is essential, and research efforts should prioritize the development of more effective therapeutic strategies to benefit all patients.

show abstract

“…Both atypical endometriosis and atypical adenofibroma of the ovary have been considered as precancerous lesions [4,5]. Another distinctive feature is the association between the presence of thromboembolism and a poor prognosis in OCCC [6,7], but the biological mechanism of hypercoagulation in OCCC remains unclear [8]. CA 125, the standard tumor marker for high grade serous carcinoma, is elevated only in about 57% of OCCC [9].…”

Section: Introductionmentioning

confidence: 99%

The Surgical, Histopathological Characteristics, and Survival Outcome of Ovarian Clear Cell Carcinoma: A Retrospective Case Series Sharing the Experience of a Tertiary Cancer Centre over 10 Years

Tawab¹,

Nistor²,

Roux³

et al. 2023

Preprint

View full text Add to dashboard Cite

A retrospective study including 49 women with ovarian clear cell carcinoma between January 2009 and December 2021 at Oxford cancer centre was done. The mean age was 63 years, with 78% post-menopausal. All women underwent cytoreductive surgery with no residual disease (R0) in 39 women. The follow-up time ranged between 12-144 months, with mean of 105.5 months. The 3-year OS was 73.4%, and 3-year PFS was 81.3%, with a mean of 101.7months (95%CI, 84.63-118.93). As expected, women with stage 1 disease had the best outcome. In comparing OS in respect to absence or presence of residual disease, the 3-year OS was 88.6% (95% CI 108.6-141.8), compared to 12.5% (95% CI 4.48-32.11) respectively (P<0.001). In multivariant analysis the variables included were CA 125 (< or >200 IU/ml), Hb (< or >115 g/L), albumin (< or >40 g/L), associated endometriosis, ascites, residual disease, and FIGO staging. FIGO stage was the only independent prognostic indicator of OS with (p<0.05). Surgery to achieve no residual tumour is necessary to improve the prognosis in advanced OCCC. At present, the true challenge is to predict which patients with early-stage disease are at higher risk of recurrence and would most benefit from adjuvant treatments.

show abstract

Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma

Cited by 8 publications

References 40 publications

Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1α and tumor progression of clear cell ovarian cancer

Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1α and tumor progression of clear cell ovarian cancer

From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer

The Surgical, Histopathological Characteristics, and Survival Outcome of Ovarian Clear Cell Carcinoma: A Retrospective Case Series Sharing the Experience of a Tertiary Cancer Centre over 10 Years

Contact Info

Product

Resources

About